Myomo
17 hedge funds and large institutions have $2.85M invested in Myomo in 2022 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 5 closing their positions.
1.13% less ownership
Funds ownership: 26.3% → 25.16% (-1.1%)
8% less capital invested
Capital invested by funds: $3.09M → $2.85M (-$234K)
19% less funds holding
Funds holding: 21 → 17 (-4)
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
Top Buyers
| 1 |
Renaissance Technologies
New York
|
+$28.8K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$583 |
Top Sellers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$69.2K |
| 2 |
VF
Virtu Financial
New York
|
-$25K |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$17K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$97 |
| 5 |
Wells Fargo
San Francisco,
California
|
-$11 |
MYO Hedge Fund Activity: Q3 2022 in Review
17 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Myomo (MYO) for Q3 2022, worth a combined $2.85M — down 7.6% from $3.09M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of MYO and 1 opened new positions — a net loss of 4 holders — while 4 trimmed existing stakes and 1 added.
The largest buyer was Renaissance Technologies, adding an estimated $28.8K. The largest seller was Vanguard Group, cutting an estimated $69.2K.
- 17 institutional investors held Myomo (MYO) as of Q3 2022, down from 21 in Q2 2022.
- Funds reported $2.85M of Myomo stock for Q3 2022, down 7.6% quarter-over-quarter.
- 1 fund opened new Myomo positions in Q3 2022 and 5 closed out, a net change of -4 holders.
- The largest Myomo buyer in Q3 2022 was Renaissance Technologies, an estimated $28.8K added.
- The largest Myomo seller in Q3 2022 was Vanguard Group, an estimated $69.2K sold.
Based on aggregated 13F filings for Q3 2022.